Daewoong Pharmaceutical reveals Phase 2 patient data for IPF drug Versiforosin

Daewoong Pharmaceutical has released the baseline clinical and functional characteristics of 104 patients enrolled in its global Phase 2 clinical trial for Versiforosin (DWN12088), a candidate drug for Idiopathic Pulmonary Fibrosis (IPF). The data was presented at the European Respiratory Society (ERS) 2026 meeting in Barcelona.

The study group consists of 55 patients from South Korea (52.9%) and 49 from the United States (47.1%). Among the participants, 71 patients (68.3%) were already using existing anti-fibrotic agents, while 33 (31.7%) were not. The average Forced Vital Capacity (FVC) was approximately 77% of the predicted normal, and the Diffusing Capacity of the Lungs for Carbon Monoxide (DLCO) was approximately 51%.

Versiforosin functions by selectively inhibiting Prolyl-tRNA Synthetase (PRS) to reduce excessive collagen production. Unlike existing treatments, it targets the final collagen synthesis stage, allowing for potential use as a monotherapy or in combination with current drugs. The candidate has received Orphan Drug and Fast Track designations from the U.S. FDA and Orphan Drug designation from the EMA. Daewoong Pharmaceutical expects to announce top-line results from the Phase 2 trial in the first half of 2027.